A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease.
Phase of Trial: Phase III
Latest Information Update: 18 May 2018
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms GRADUATE-1
- Sponsors Roche
- 14 May 2018 Status changed from not yet recruiting to recruiting.
- 16 Apr 2018 Planned number of patients changed from 750 to 760.
- 26 Feb 2018 New trial record